With a proactive, realistic plan, patients can protect their appearance while enjoying the metabolic and cardiovascular benefits of GLP-1s
The Wegovy pill (oral semaglutide 25 mg) produced an average weight loss of 13.6% in the OASIS 4 trial, broadly the same as the standard 2.4 mg injection and less than Mounjaro or the 7.2 mg injection
When deciding between shots and pills, your choice will ultimately depend on your medical eligibility, lifestyle, and preferences
On average, tirzepatide produces more weight loss at maximum dose
Do not exceed the recommended daily dose RA* Recommended Allowance Orange and Cherry flavour ingredients : 74.7% L-Carnitine-L-Tartar, flavourings, maltodextrin, colouring - E 150d (for taste: cola)
When is Wegovy launched in the UK